Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Javed Shaikh, Director of RWE & HEOR, Axtria, explains how harnessing next-generation sequencing and AI-powered analytics ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 7.31%, which has investors questioning if this is right time to ...

Orion Portfolio Solutions LLC reduced its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 8.6% ...

KLP Kapitalforvaltning AS acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) in the ...

The results are a boost for 4DMT after another of its lead gene therapy candidates – Fabry disease cardiomyopathy therapy 4D-310 – was placed on clinical hold by the FDA last year, after cases ...

The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing ...

RICHMOND, Calif., April 03, 2025--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM RICHMOND, Calif.

How will the work done at the division contribute to the existing work in Fabry disease ... antibodies, or gene therapies? As noted, for right now our priority focus is on research and product ...